Production of antibodies against multipass membrane proteins expressed in human tumor cells using dendritic cell...

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Antibody-mediated therapies are established treatments for human malignant tumors.
• Generating antibodies against extracellular domains of multipass plasma membrane proteins on tumors is challenging.
• Dendritic cells (DCs) are potent antigen-presenting cells that can be used for immunization.

Purpose of the Study:

• To develop an effective method for generating antibodies against extracellular domains of multipass plasma membrane proteins specifically expressed in malignant tumors.
• To evaluate the utility of dendritic cells (DCs) for immunization against tumor-associated antigens.
• To produce antibodies targeting STEAP1, STEAP4, and PSGR, which are expressed in malignant tumors.

Main Methods:

• Dendritic cells (DCs) were transduced with genes encoding STEAP1, STEAP4, and PSGR.
• Mice were immunized with these genetically modified DCs.
• Booster immunizations were performed using plasmids encoding the target proteins.

Main Results:

• The immunization strategy successfully generated significant amounts of antibodies against STEAP1, STEAP4, and PSGR in mice.
• Antibodies produced were reactive to the extracellular regions of these multipass plasma membrane proteins.
• The study demonstrated the feasibility of using DC-based immunization for antibody generation.

Conclusions:

• Dendritic cell (DC) immunization is an effective approach for producing antibodies against extracellular domains of multipass plasma membrane proteins.
• This method holds potential for developing novel antibody-mediated antitumor therapies.
• Targeting tumor-specific membrane proteins via DC-generated antibodies offers a promising avenue for cancer treatment.